Raquel Sainz-Amo
YOU?
Author Swipe
View article: New serum soluble factors predicting inflammatory and non-inflammatory disability worsening in multiple sclerosis
New serum soluble factors predicting inflammatory and non-inflammatory disability worsening in multiple sclerosis Open
Introduction Serum neurofilament light chains (sNfL) and glial fibrillary acidic protein (sGFAP) associate respectively with acute inflammation and smoldering disease in relapsing-remitting multiple sclerosis (MS) patients. We explored the…
View article: Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosis
Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosis Open
Background Serum biomarkers as neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) enabled early identification of multiple sclerosis (MS) patients at risk of relapse-associated worsening (RAW) or progression indep…
View article: Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis Open
[This corrects the article DOI: 10.3389/fimmu.2024.1480676.].
View article: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis Open
Objective To ascertain the changes of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) values in relapsing–remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and their association with t…
View article: Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis
Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis Open
microRNAs (miRNAs) are promising biomarkers for many diseases, including multiple sclerosis (MS). The neurofilament light chain (NfL) is a biomarker that can detect axonal damage in different neurological diseases. The objective of this st…
View article: COVID-19 vaccines are not associated with axonal injury in patients with multiple sclerosis
COVID-19 vaccines are not associated with axonal injury in patients with multiple sclerosis Open
Objective To evaluate the safety of COVID-19 vaccines in patients with multiple sclerosis (MS) by assessing their impact on serum neurofilament light chain (sNfL) levels as a marker of neuroaxonal damage. Methods Single-center observationa…
View article: Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis
Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis Open
Introduction Alemtuzumab is a highly effective pulsed immune reconstitution therapy for multiple sclerosis (MS). Aim To evaluate serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) in patients with rela…
View article: Establishing Normal Serum Values of Neurofilament Light Chains and Glial Fibrillary Acidic Protein Considering the Effects of Age and Other Demographic Factors in Healthy Adults
Establishing Normal Serum Values of Neurofilament Light Chains and Glial Fibrillary Acidic Protein Considering the Effects of Age and Other Demographic Factors in Healthy Adults Open
Multiple studies have shown the importance of blood-based biomarkers indicating axonal damage (serum neurofilament light chains [sNfL]) or astroglia activation (serum glial fibrillary acidic protein [sGFAP]) for monitoring different neurol…
View article: Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis
Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis Open
Introduction The immunoglobulin kappa free light chain (KFLC) index has been proposed as a potentially suitable alternative to oligoclonal IgG bands (OCGB) for diagnosing multiple sclerosis (MS), offering automation and reduced processing …